



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Head. Off.: 817 8th floor Sakar 9 NR Old Reserve Bank Opp Time of India Ahmedabad Gujarat 380009

Branch Off.: 405 Marvella business hub Opp pal rto, pal , adajan , surat 395009

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Date: 11th July, 2024

To,
The General Manager,
Corporate Relationship Department,
BSE Limited
25th Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Reference: ISIN: INE331C01017; Scrip Code: 524661 Symbol : WELCURE;

Subject: Statement of Investor Grievances under Regulation 13 (3) of SEBI and Disclosure Requirement) Regulation, 2015

Dear Sir/Ma'am,

The statement of Investor Grievances pursuant to Regulation 13 (3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 as provided by our Registrar and Transfer Agent M/s Skyline Financial Services Private Limited for the quarter ended 30th June, 2024 as follows

Pending at the beginning of the quarter	0
Received during the quarter	0
Disposed off during the quarter	0
Remaining unresolved at the end of the quarter	0

You are requested to take the same into your records and acknowledge.

Kindly take this intimation in record in compliance with applicable statutory provisions.

Thanking you,
Yours truly,

For Welcure Drugs & Pharmaceuticals Ltd.


Altaf Hussain Shah
Managing Director and CFO
DIN: 10351528

July 3, 2024

REF: SFSPL/QTR/June/2024

COMPANY SECRETARY
WELCURE DRUGS & PHARMACEUTICALS LIMITED
33/36 BASEMENT (BACK SIDE),
WEST PATEL NAGAR NEAR RAM
JASS GROUND, DELHI 11000B.

Sub: Statement of Investor Complaints as per Regulation 13(3) of (LODR), 2015

Dear Sir/Madam,

This is to inform you that our Company **WELCURE DRUGS & PHARMACEUTICALS LIMITED** having **CIN: L24232DL1996PLC227773** is registered on the SCORES platform of the SEBI in order to handle investor's complaints electronically.

As required under regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is the list of complaints received from complainants, complaints resolved as pending for consideration.

Number of investors complaints pending at the beginning of the quarter starting from 1st April, 2024	Complaints received during the Quarter From 1st April, 2024 To 30th June, 2024	Complaints disposed of during the Quarter From 1st April, 2024 To 30th June, 2024	Complaints remaining unresolved at the end of Quarter Ended on 30th June, 2024
NIL	NIL	NIL	NIL


Please find the details hereunder :-

S.No.	Received From	Pending at the end of last quarter	Received During the Quarter	Resolved	Total Pending
1	Directly from Investors	NIL	NIL	NIL	NIL
2	SEBI SCORES	NIL	NIL	NIL	NIL
3	Stock Exchanges	NIL	NIL	NIL	NIL
4	Other Sources (if Any)	NIL	NIL	NIL	NIL
5	Grand Total	NIL	NIL	NIL	NIL

We hereby certify that we have NIL pending complaints at our end for the period.

Thanking you,

For Skyline Financial Services Pvt. Limited


Vijay Kumar
(Authorised Signatory)
Investor Grievances Cell

